Proteome Sciences plc Provides Earnings Guidance for the Year Ended December 31, 2020

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.